title: Resumption of menstruation after amenorrhea in women treated by endometrial ablation and myometrial resection.
abstract: OBJECTIVE
  To evaluate the prevalence of resumption of menstruation after an interval of amenorrhea in women treated by endometrial ablation and myometrial resection.
  
  
  METHODS
  Retrospective analysis.
  
  
  METHODS
  Tertiary care university-affiliated teaching hospital.
  
  
  METHODS
  One hundred fifty-seven consecutive patients treated for menorrhagia refractory to medical therapy.
  
  
  METHODS
  Loop resection or rollerball ablation of the endometrium.
  
  
  RESULTS
  At 6 to 12 months postoperatively, 50. 6% of patients were amenorrheic and 35.1% had hypomenorrhea. Over follow-up of 13 to 30 months, 45.1% of women became amenorheic and 40.5% had satisfactory hypomenorrhea. Resumption of menstruation after any interval of amenorrhea occurred in 27.2% of amenorheic patients. We observed an increasing trend to resumption of menstruation after rollerball ablation (29.4%) compared with loop resection (26.7%) and after preoperative endometrial suppression with buserelin (37.5%) and leuprolide (27.1%) compared with danazol (12.5%) and goserelin (10.5%). Resumption of menstruation occurred in 44.4% of women who did not have preoperative endometrial suppression.
  
  
  CONCLUSIONS
  Our results suggest that resumption of menstruation does occur after a variable interval of amenorrhea following endometrial ablation and myometrial resection. It could potentially be used as a marker of failure of endometrial destruction.
authors.affiliation: Department of Obstetrics and Gynecology, Columbia Michael Reese Hospital, 2929 South Ellis, Chicago, IL 60616, USA.
authors.forename: R C
authors.initials: RC
authors.lastname: Seeras
authors.forename: G B
authors.initials: GB
authors.lastname: Gilliland
mesh_terms: D000568:Amenorrhea / Q000209:etiology*; D002064:Buserelin / Q000627:therapeutic use; D003613:Danazol / Q000627:therapeutic use; D004564:Electrocoagulation; D004717:Endometrium / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008595:Menorrhagia / Q000601:surgery*; D009215:Myometrium / Q000601:surgery*; D011183:Postoperative Complications / Q000453:epidemiology*; D011300:Preoperative Care; D012189:Retrospective Studies; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D017273:Goserelin; D016729:Leuprolide; D003613:Danazol; D002064:Buserelin